Form 4: Xenon Pharmaceuticals Director Steven Gannon Exercises Stock Options
SEC Form 4 Filing
Director Steven Gannon exercised stock options to acquire 5,144 common shares of Xenon Pharmaceuticals at $12.57 per share on May 14, 2025.
Summary
- On May 14, 2025, Steven Gannon, a director of Xenon Pharmaceuticals Inc., exercised stock options.
- This transaction involved the acquisition of 5,144 common shares at a price of $12.57 per share.
- Following the transaction, Gannon directly owns 7,144 common shares.
- The exercised stock options were fully vested and exercisable as of the transaction date.
Sentiment
Score: 5
Explanation: Neutral sentiment as it is a standard disclosure of stock option exercise.
Positives
- The exercise of vested stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's activity in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date of the stock option exercise and acquisition of common shares. |
| 05/16/2025 | Date of signature for the Form 4 filing. |
| 05/20/2025 | Expiration date of the stock options. |
Keywords
Xenon Pharmaceuticals, Director, Stock Options, Common Shares, Beneficial Ownership, Form 4, Gannon, XENE
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.